Establishment of ProNephro AKI (NGAL) Cut Off Value for Risk Assessment of Moderate to Severe Acute Kidney Injury in Adults

Last updated: November 18, 2025
Sponsor: BioPorto Diagnostics
Overall Status: Active - Not Recruiting

Phase

N/A

Condition

Renal Failure

Kidney Failure

Kidney Disease

Treatment

ProNephro AKI (NGAL)

Clinical Study ID

NCT06652100
TD-0475
  • Ages > 22
  • All Genders

Study Summary

The purpose of this research is to collect blood and urine from adult patients admitted to an intensive care unit. This is to assess the performance of the ProNephro AKI (NGAL) assay (lab test) as an aid to identify patients at risk for acute kidney injury.

Eligibility Criteria

Inclusion

Inclusion Criteria:

Male and females ≥ 22 years of age. Subjects must be admitted to an Intensive Care Unit and must have a urine sample collected within 24 hours of ICU admission.

Subjects must have at least one of the following leading to admission to the ICU, or occurring within 24 hours of admission to the ICU:

  • Vasoactive medication administration

  • Mechanical ventilation

  • Hypoxemia requiring oxygen support therapy including Bilevel positive airwaypressure (BIPAP) and high flow nasal canula

  • Mean arterial pressure (MAP) less than 60 (within 12 hrs. of ICU admission only)

  • Serum Lactate greater than 2.5 mmol/L

  • History of solid organ transplantation, renal transplantation included only if morethan 3 months prior

  • History of bone marrow transplantation Subject with signed informed consent.

Exclusion

Exclusion Criteria:

Special populations including pregnant and lactating women, prisoners, or institutionalized individuals.

Subjects receiving Kidney Replacement Therapy in the first 24 hours of ICU admission.

Subjects diagnosed with active Urinary Tract Infection per institute standard of care at the time of NGAL sampling.

Subjects with a known history of chronic kidney disease stages 4 and 5 as evidenced by a pre-enrollment estimated GFR of less than 30 mL/min/1.73M2 and under the care of a nephrologist.

Subjects with any known urothelial, urological or kidney malignancies. Subjects that have had any urologic procedure or urologic surgery immediately prior to admission to the ICU.

Subjects that have had surgical nephrectomy less than 3 months prior to admission.

Subjects that have been previously enrolled in this study. Subjects that do not have a baseline sCR within 6 months prior to ICU admission available.

Subjects that did not sign the informed consent. Subjects enrolled in an interventional pharmaceutical or device clinical trial at time of ICU admission

Study Design

Total Participants: 800
Treatment Group(s): 1
Primary Treatment: ProNephro AKI (NGAL)
Phase:
Study Start date:
October 28, 2024
Estimated Completion Date:
January 31, 2026

Connect with a study center

  • The University of Alabama

    Birmingham, Alabama 35233
    United States

    Site Not Available

  • The University of Alabama

    Birmingham 4049979, Alabama 4829764 35233
    United States

    Site Not Available

  • UC Davis

    Sacramento, California 95817
    United States

    Site Not Available

  • UC Davis

    Sacramento 5389489, California 5332921 95817
    United States

    Site Not Available

  • Yale University

    New Haven, Connecticut 06510
    United States

    Site Not Available

  • Yale University

    New Haven 4839366, Connecticut 4831725 06510
    United States

    Site Not Available

  • University of Chicago

    Chicago, Illinois 60637
    United States

    Site Not Available

  • University of Chicago

    Chicago 4887398, Illinois 4896861 60637
    United States

    Site Not Available

  • Johns Hopkins University

    Baltimore, Maryland 21224
    United States

    Site Not Available

  • Johns Hopkins University

    Baltimore 4347778, Maryland 4361885 21224
    United States

    Site Not Available

  • Massachusetts General Hospital

    Boston, Massachusetts 02114
    United States

    Site Not Available

  • Massachusetts General Hospital

    Boston 4930956, Massachusetts 6254926 02114
    United States

    Site Not Available

  • University of Michigan

    Ann Arbor, Michigan 48109
    United States

    Site Not Available

  • University of Michigan

    Ann Arbor 4984247, Michigan 5001836 48109
    United States

    Site Not Available

  • University of New Mexico

    Albuquerque, New Mexico 87131
    United States

    Site Not Available

  • University of New Mexico

    Albuquerque 5454711, New Mexico 5481136 87131
    United States

    Site Not Available

  • Columbia University

    New York, New York 10032
    United States

    Site Not Available

  • Columbia University

    New York 5128581, New York 5128638 10032
    United States

    Site Not Available

  • Wake Forest University

    Winston-Salem, North Carolina 27109
    United States

    Site Not Available

  • Wake Forest University

    Winston-Salem 4499612, North Carolina 4482348 27109
    United States

    Site Not Available

  • Cleveland Clinic

    Cleveland, Ohio 44195
    United States

    Site Not Available

  • Cleveland Clinic

    Cleveland 5150529, Ohio 5165418 44195
    United States

    Site Not Available

  • Medical University of South Carolina

    Charleston, South Carolina 29425
    United States

    Site Not Available

  • Medical University of South Carolina

    Charleston 4574324, South Carolina 4597040 29425
    United States

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.